Blue Cross and Blue Shield of Louisiana has filed a case against Bristol Myers Squibb alleging the company conducted patent fraud to extend protections for its multiple myeloma drug Pomalyst.
https://www.pharmalive.com/wp-content/uploads/2023/05/BMS-building.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-07 08:57:552023-09-07 08:58:13BMS accused by HMO of patent fraud to allegedly sustain pomalyst monopoly
